Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy

Abstract Background Treatment with anti-PD1 monoclonal antibodies improves the survival of metastatic melanoma patients but only a subgroup of patients benefits from durable disease control. Predictive biomarkers for durable benefit could improve the clinical management of patients. Methods Plasma s...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Teofila Seremet, Yanina Jansen, Simon Planken, Hassan Njimi, Mélanie Delaunoy, Hakim El Housni, Gil Awada, Julia Katharina Schwarze, Marleen Keyaerts, Hendrik Everaert, Danielle Lienard, Véronique Del Marmol, Pierre Heimann, Bart Neyns
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	BMC 2019-09-01
Σειρά:	Journal of Translational Medicine
Θέματα:	Translational research Liquid biopsy Circulating tumor DNA Monitoring Immunotherapy Metastatic melanoma
Διαθέσιμο Online:	http://link.springer.com/article/10.1186/s12967-019-2051-8
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!